Boehringer Ingelheim yesterday announced the expansion of its Animal Health business in China. One of the major moves is the opening of the Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai.
ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
US – Governor Terry E. Branstad travelled to Sioux Center last week to attend the grand opening for one of three Boehringer Ingelheim Vetmedica, Inc. (BIVI) specialised vaccine research facilities.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
US - With the recent increase in porcine epidemic diarrhea virus (PEDv) cases reported this spring, the latest At The Meeting (ATM) with the Morrison Group audio program provides an update on developments in case reporting, effective control steps and immunology in the last year.
BECAL (The Boehringer Ingelheim Economic Calculator) was created in collaboration with industry experts to provide a convenient tool for the economic analysis of vaccination interventions. BECALsow looks at health interventions in the sow herd and evaluates preventative health measures by easily calculating the return of investment based on production data.
Read and download the posters.
Get the latest news on Swine Health Subscribe to our newsletter